TY - JOUR
T1 - Defining the disease course of TNFα blockers-associated Multiple Sclerosis
AU - Lucchini, Matteo
AU - Giuffre', Guido Maria
AU - Nociti, Viviana
AU - Bianco, Assunta
AU - De Fino, Chiara
AU - Losavio, Francesco Antonio
AU - Presicce, Giorgia
AU - Calabresi, Paolo
AU - Mirabella, Massimiliano
PY - 2021
Y1 - 2021
N2 - Tumour Necrosis Factor alpha (TNFalpha) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFalpha blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFalpha blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFalpha blockers-associated Multiple Sclerosis.
AB - Tumour Necrosis Factor alpha (TNFalpha) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFalpha blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFalpha blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFalpha blockers-associated Multiple Sclerosis.
KW - Central nervous system (CNS) inflammatory disorders
KW - Demyelinating disorders
KW - Multiple sclerosis
KW - Rheumatological disorders
KW - TNFα
KW - Tumour necrosis factor alpha blockers
KW - Central nervous system (CNS) inflammatory disorders
KW - Demyelinating disorders
KW - Multiple sclerosis
KW - Rheumatological disorders
KW - TNFα
KW - Tumour necrosis factor alpha blockers
UR - http://hdl.handle.net/10807/170068
U2 - 10.1016/j.jneuroim.2021.577525
DO - 10.1016/j.jneuroim.2021.577525
M3 - Article
SN - 0165-5728
VL - 353
SP - 577525-N/A
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
ER -